Log in

Relevant bibliographies by topics / P 90.5 UL 2011 R677

Contents

Journal articles

Academic literature on the topic 'P 90.5 UL 2011 R677'

Author: Grafiati

Published: 4 June 2021

Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'P 90.5 UL 2011 R677.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "P 90.5 UL 2011 R677"

1

Li, Mingjia, Aziz Nazha, Paul Elson, et al. "A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients." Blood 124, no. 21 (2014): 5252. http://dx.doi.org/10.1182/blood.v124.21.5252.5252.

Full text

Abstract:

Abstract Introduction: Traditional prognostic factors for adult acute lymphocytic leukemia (ALL) include age, white blood count at diagnosis, and cytogenetic (CG) risk. We sought to identify a more detailed prognostic risk score for newly diagnosed adult patients (pts) based on these and other pre-treatment characteristics. Methods: 82 newly diagnosed ALL pts given induction chemotherapy (IC) at our institution between the years 2003-2011 were included, and data were obtained by chart review. Institutional review board approval was obtained. Variables examined included: gender, age, immunophen

APA, Harvard, Vancouver, ISO, and other styles

2

Ayello, Janet, Yaya Chu, Carolyn A. Keever-Taylor, et al. "Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)." Blood 128, no. 22 (2016): 1245. http://dx.doi.org/10.1182/blood.v128.22.1245.1245.

Full text

Abstract:

Abstract Background: SCD is characterized by chronic vaso-occlusive crises and multiorgan failure resulting in poor quality of life and early mortality (Bhatia/Cairo et al, BMT 2014). There is presently no curative therapy for patients with high risk SCD other than HLA-identical sibling AlloSCT. (Freed/Cairo et al BMT 2012). However, less than 15% of eligible SCD patients have an unaffected MSD with a 10-15% increase of graft failure and TRM (Talano/Cairo et al, EJH, 2015). Similarly, most patients lack a matched related donor and UCB is an inferior source in SCD recipients (Radhakrishman/Cair

APA, Harvard, Vancouver, ISO, and other styles

3

Loh, Mignon L., Elizabeth Raetz, Meenakshi Devidas, et al. "Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group." Blood 128, no. 22 (2016): 451. http://dx.doi.org/10.1182/blood.v128.22.451.451.

Full text

Abstract:

Abstract Survival for childhood acute lymphoblastic leukemia (ALL) now approaches 90% with risk adapted therapy based on National Cancer Institute risk group (NCI RG) at diagnosis, somatic lymphoblast genetics, and early response to therapy as measured by minimal residual disease (MRD). The Children's Oncology Group AALL03B1 ALL Classification trial enrolled 11,145 children, adolescents, and young adults less than 31 years of age with newly diagnosed B- or T-lineage ALL between December 2003 and September 2011. Companion therapeutic trials for B-lineage ALL included AALL0331 (n= 5226) for NCI

APA, Harvard, Vancouver, ISO, and other styles

4

Gaziev, Javid, Antonella Isgrò, Pietro Sodani та ін. "Long-Term Outcome after Haploidentical Hematopoietic Cell Transplantation Utilizing CD34+ Selected/CD3CD19+ Depleted or Tcrαβ+/CD19+ Depleted Grafts in Pediatric Patients with Hemoglobinopathies". Blood 130, Suppl_1 (2017): 663. http://dx.doi.org/10.1182/blood.v130.suppl_1.663.663.

Full text

Abstract:

Abstract Introduction. Limited data exist regarding the role of haploidentical HCT (haplo-HCT) in hemoglobinopathies, whereas long-term outcomes and late effects among these patients are largely unknown. We compared long-term outcomes in two groups of patients underwent halpo-HCT using different in vitro depletion strategies. Methods . Fifty four consecutive patients, aged &lt;17 years, received a haploidentical (≥2 HLA-mismatched antigens) transplant for thalassemia (n=45) or sickle cell disease-SCD (Hb SS, n=7 and HbS/beta thalassemia, n=2). Among these patients 32 received CD34+ selecte

APA, Harvard, Vancouver, ISO, and other styles

5

Sheth, Kruti, Raffaele Girlanda, and Catherine Broome. "Long-Term Management of Atypical Hemolytic Uremic Syndrome after Non-Renal Solid Organ Transplantation with Eculizumab." Blood 126, no. 23 (2015): 3466. http://dx.doi.org/10.1182/blood.v126.23.3466.3466.

Full text

Abstract:

Abstract Thrombotic microangiopathy (TMA) defined as microangiopathic hemolytic anemia, thrombocytopenia and end organ damage has been described in the post transplant (PT) setting after solid organ and hematopoietic stem cell transplants (HSCT). The true incidence among non-renal solid organ transplant (NRSOT) recipients is unknown. Reported rates range from 2-30% (Verbiest 2014). Despite standard interventions such as plasma exchange and/or reduction in calcineurin inhibitor (CNI) therapy, 3-month mortality rates remain as high as 40% in NRSOT patients who develop PT-TMA. In HSCT and renal t

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Junmei, Tahsin Özpolat, Colette Norby, et al. "N-Acetylcysteine Treatment in Two Patients with Relapsed Thrombotic Thrombocytopenic Purpura Increased ADAMTS13 Activity, Free Thiol Concentration in Plasma, and Inhibited Platelet Activation." Blood 126, no. 23 (2015): 239. http://dx.doi.org/10.1182/blood.v126.23.239.239.

Full text

Abstract:

Abstract Introduction: Thrombotic thrombocytopenic purpura (TTP) is a catastrophic and potentially fatal disorder caused by systemic microvascular thrombosis due to von Willebrand factor (VWF)-platelet thrombi. TTP is caused by congenital or acquired deficiency of the plasma metalloprotease ADAMTS13. Based on an earlier study (Chen J et al., J Clin Invest 2011, 121:593-603), we proposed N-acetylcysteine (NAC) as an adjunct treatment for TTP. This study showed that NAC reduced the size and activity of VWF in vitro in human plasma and in vivo in a TTP mouse model. In 2013 and 2014, two case repo

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!